|
 Press Releases:
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Genta's website for historical purposes only. Genta assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
Press Releases for the last 60 days.
June 24th, 2008
Genta Updates Progress of its Phase 3 Trial of Genasense® in Patients with Advanced Melanoma |
June 23rd, 2008
FDA Lifts Clinical Hold on Genta’s Tesetaxel, a Leading Oral Taxane |
June 10th, 2008
Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane |
June 9th, 2008
Genta Announces First Closing of its $40 Million Convertible Financing Facility; Issues $20 Million in Senior Secured Convertible Notes |
June 6th, 2008
Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia |
June 5th, 2008
Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs |
June 2nd, 2008
Genta Announces Initial Clinical Trial Results for G4544, a Novel Potent Drug for Bone Disease |
May 30th, 2008
Genasense® Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma |
May 29th, 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense® is Associated with Significantly Increased Survival in All Responders |
May 21st, 2008
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology |
May 8th, 2008
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights |
May 6th, 2008
Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board |
May 6th, 2008
Genta Announces Transfer of its Common Stock to the OTC Bulletin Board |
Archived Press Releases
|
Investor Relations 
